WaveMan
WaveMan · Company
GYRE · Gyre Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

GYRE Gyre Therapeutics (GYRE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001124105
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
45
13F, latest reported quarter
Conversions, 180 days
16
Codes C/M, not in net · $103.1K priced

What the filings say about GYRE

Insiders, 180 days
-$952.9K net sold
2 sellers · 0% of sales under a 10b5-1 plan

Gyre Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, GYRE THERAPEUTICS, INC. insiders sold a net $952.9K of stock across 110 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Ye Weiguo
Chief Operating Officer
SELL
2026-06-22 SECtraded 2026-06-18
3,000
$19.1K
-1.0%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Jun 11, 2026.
  • The trade is 0.4% of the 700,000 shares held after it.
  • No other insider sold within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Ye Weiguo sold about $19.1K of GYRE on Jun 18, 2026; 45 funds added in the latest 13F quarter.
Ye Weiguo
Chief Operating Officer
SELL
2026-06-15 SECtraded 2026-06-11
2,800
$17.3K
+4.3%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Jun 10, 2026.
  • The trade is 0.4% of the 700,000 shares held after it.
  • No other insider sold within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Ye Weiguo sold about $17.3K of GYRE on Jun 11, 2026; 45 funds added in the latest 13F quarter.
Ye Weiguo
Chief Operating Officer
SELL
2026-06-22 SECtraded 2026-06-10
5,000
$31.2K
-1.0%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Jun 9, 2026.
  • The trade is 0.7% of the 700,000 shares held after it.
  • No other insider sold within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Ye Weiguo sold about $31.2K of GYRE on Jun 10, 2026; 45 funds added in the latest 13F quarter.
Ye Weiguo
Chief Operating Officer
SELL
2026-06-11 SECtraded 2026-06-10
6,418
$39.9K
+2.4%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Jun 9, 2026.
  • The trade is 0.9% of the 700,000 shares held after it.
  • No other insider sold within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Ye Weiguo sold about $39.9K of GYRE on Jun 10, 2026; 45 funds added in the latest 13F quarter.
Ye Weiguo
Chief Operating Officer
SELL
2026-06-22 SECtraded 2026-06-09
3,000
$18.4K
-1.0%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Jun 5, 2026.
  • The trade is 0.4% of the 700,000 shares held after it.
  • No other insider sold within 30 days.
  • 45 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Ye Weiguo sold about $18.4K of GYRE on Jun 9, 2026; 45 funds added in the latest 13F quarter.
110 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 105 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$952.9K over 180 days
below 62% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
45 funds bought in last quarter
below 55% of Pharma & Biotech
Revenue
+10.2% year over year
more than 59% of Pharma & Biotech
Margin
8.5% net margin
more than 80% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
5.3% of the float short (float per yahoo 2026-10-26) · 6.9 days to cover · settled 2026-09-30
below 68% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 18 in the prior 90
Why it matters
The absence is the signal: 18 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch GYRE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-26.2%12M
-32%-19%-7%+6%2025-102025-122026-022026-042026-062026-082026-10 2026-06-04 · Ye Weiguo sold $120.0K2026-05-14 · Ye Weiguo sold $107.7K2026-06-05 · Ye Weiguo sold $98.6K2026-06-09 · Ye Weiguo sold $89.0K2026-05-15 · Ye Weiguo sold $87.1K2026-05-06 · Luo Ying sold $81.5K2026-05-21 · Ye Weiguo sold $78.8K2026-05-19 · Ye Weiguo sold $58.1K2026-05-20 · Ye Weiguo sold $57.8K2026-06-10 · Ye Weiguo sold $39.9K2026-06-10 · Ye Weiguo sold $31.2K2026-05-26 · Ye Weiguo sold $24.4K2026-05-22 · Ye Weiguo sold $21.3K2026-06-18 · Ye Weiguo sold $19.1K2026-06-09 · Ye Weiguo sold $18.4K2026-06-11 · Ye Weiguo sold $17.3K2026-05-05 · Luo Ying sold $1.4K2026-05-18 · Ye Weiguo sold $1.3K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns GYRE: institutional holders (13F)

13F holdings, latest reported quarter
HSG Holding Ltd
3,750,299 sh
$24.7M
BlackRock, Inc.
993,943 sh
$6.6M
Octagon Capital Advisors LP
954,416 sh
$6.3M
VANGUARD CAPITAL MANAGEMENT LLC
876,927 sh
$5.8M
GEODE CAPITAL MANAGEMENT, LLC
532,950 sh
$3.5M

Congress trades in GYRE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

GYRE planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

GYRE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Innovator U.S. Small Cap Managed 10 Buffer ETF
$5.1K position · as of 2026-07-31
0.0%
GuideMark Small/Mid Cap Core Fund
$23.3K position · as of 2026-06-30
0.0%
WisdomTree U.S. SmallCap Fund
$129.9K position · as of 2026-06-30
0.0%
Small Cap Core Fund
$43.4K position · as of 2026-06-30
0.0%
ATM Small Cap Managed Volatility Portfolio
$57.8K position · as of 2026-06-30
0.0%
iShares Russell 2000 Growth ETF
$795.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $952.9K sold by insiders over 180 days, 45 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

GYRE financials

Revenue growth
+10.2%
XBRL, annual
Net margin
8.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Free cash flow, TTM
-$6.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on assets
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-0.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$116.6M$105.8M$113.5M$102.3M
Gross profitn/a$101.9M$108.8M$97.5M
Operating income$11.5M$16.2M-$67.2M$9.2M
Net income$9.9M$17.9M-$85.5M$4.3M
EPS (diluted)0.020.05-1.410.03
Operating cash flow$1.0M-$3.6M$25.9M$10.7M
Cash$49.2M$11.8M$33.5M$25.2M
Dividends paidn/an/an/a$45.0M
SEC XBRL, fiscal years, as known on 2026-10-28

GYRE Stock Sonar score 4/7 axes

Find similar shapesCompare

GYRE ranks highest on growth (59th percentile) and risk and compliance (50th), and lowest on insider conviction (18th), among Pharma & Biotech peers.

Growth
59
Inputs
  • Revenue growth, YoY+10.2% · 59 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
18
Inputs
  • Net Form 4 buying (codes P and S), 180d-$953K · 36 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
45
Inputs
  • Funds adding, latest quarter45 · 45 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
50
Inputs
  • Short interest, % of float+5.3% · 57 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+12.2% · 42 pct, sector of 511
3 not measured: Profitability, Financial health, US patents
  • Profitability needs 2 of 4 inputs, 0 present: the filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

GYRE filings, in plain words

Are Gyre Therapeutics insiders buying or selling GYRE?

In the 180 days to 2026-10-28, Gyre Therapeutics insiders were net sellers, a net $952.9K across purchases and sales reported on Form 4, by 2 sellers.

Read the full summary

In the 180 days to 2026-10-28, Gyre Therapeutics insiders were net sellers of GYRE, a net $952.9K across purchases and sales reported on Form 4 by 2 sellers. None of the 18 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies